ATE356207T1 - Humanes btrcp protein - Google Patents
Humanes btrcp proteinInfo
- Publication number
- ATE356207T1 ATE356207T1 AT99901671T AT99901671T ATE356207T1 AT E356207 T1 ATE356207 T1 AT E356207T1 AT 99901671 T AT99901671 T AT 99901671T AT 99901671 T AT99901671 T AT 99901671T AT E356207 T1 ATE356207 T1 AT E356207T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- agents
- human
- peptide fragments
- hiv
- Prior art date
Links
- 102100038576 F-box/WD repeat-containing protein 1A Human genes 0.000 title 1
- 101100173415 Homo sapiens BTRC gene Proteins 0.000 title 1
- 101100010150 Niallia circulans btrC gene Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 108010033276 Peptide Fragments Proteins 0.000 abstract 3
- 102000007079 Peptide Fragments Human genes 0.000 abstract 3
- 101001030691 Homo sapiens F-box/WD repeat-containing protein 1A Proteins 0.000 abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 2
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 2
- 239000003443 antiviral agent Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102000050445 human BTRC Human genes 0.000 abstract 2
- 102000015735 Beta-catenin Human genes 0.000 abstract 1
- 108060000903 Beta-catenin Proteins 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 230000007319 proteasomal degradation pathway Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4722—G-proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9801100A FR2774377B1 (fr) | 1998-01-30 | 1998-01-30 | Proteine humaine beta-trcp de ciblage des proteines vers les voies de degradation par le proteasome |
| FR9815545A FR2774378A1 (fr) | 1998-01-30 | 1998-12-09 | PROTEINE HUMAINE BETA-TrCP DE CIBLAGE DES PROTEINES VERS LES VOIES DE DEGRADATION PAR LE PROTEASOME |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE356207T1 true ATE356207T1 (de) | 2007-03-15 |
Family
ID=26234099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99901671T ATE356207T1 (de) | 1998-01-30 | 1999-01-29 | Humanes btrcp protein |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6730486B1 (de) |
| EP (1) | EP1049775B1 (de) |
| JP (1) | JP2002501746A (de) |
| AT (1) | ATE356207T1 (de) |
| AU (1) | AU2169499A (de) |
| CA (1) | CA2370098C (de) |
| DE (1) | DE69935414T2 (de) |
| FR (1) | FR2774378A1 (de) |
| WO (1) | WO1999038969A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0920518A1 (de) | 1996-08-26 | 1999-06-09 | Signal Pharmaceuticals, Inc. | Von einem stimulus induzierbarer i(kappa)b kinase komplex |
| US20060088846A1 (en) | 1998-08-28 | 2006-04-27 | Michele Pagano | Methods to identify compounds useful for the treatment of proliferative and differentiative disorders |
| ES2361660T3 (es) * | 1998-12-10 | 2011-06-21 | Signal Pharmaceuticals Llc | Ubicutina-ligasa e3 humana para la modulación de nk-kappa b. |
| JP2011195590A (ja) * | 1999-10-20 | 2011-10-06 | Osteoscreen Inc | 骨および毛成長を刺激するためのプロテアソーム活性のインヒビター |
| FR2801902B1 (fr) * | 1999-12-01 | 2005-03-04 | Centre Nat Rech Scient | Procedes de criblages fonctionnels d'agents aptes a moduler l'activite des complexes ubiquitine-ligases scf et leurs applications |
| EP1182251A1 (de) * | 2000-08-11 | 2002-02-27 | Yissum Research Development Company of the Hebrew University of Jerusalem | Verfahren zum Identifizieren von Verbindungen, die die Ubiquitin vermittelte Proteolyse von IkB inhibieren |
| WO2002050261A2 (en) * | 2000-12-18 | 2002-06-27 | Hybrigenics | PROTEINS THAT INTERACT WITH βTRCP |
| US20030092603A1 (en) * | 2001-10-09 | 2003-05-15 | Mundy Gregory R. | Identification of specific modulators of bone formation |
| FR2859733A1 (fr) * | 2003-09-15 | 2005-03-18 | Centre Nat Rech Scient | Procede de criblage fonctionnel d'agents aptes a moduler l'activite des ubiquitine hydrolases et leurs applications |
| US7439032B2 (en) * | 2003-10-21 | 2008-10-21 | New York University | Methods to identify compounds useful for tumor sensitization to DNA damage |
| FR2867783B1 (fr) * | 2004-03-16 | 2008-02-01 | Cytomics Systems | Procede de criblage d'agent modulant l'ubiquitination de la proteine ikbalpha et moyens destines a la mise en oeuvre dudit procede |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5043262A (en) * | 1988-05-12 | 1991-08-27 | Dana Farber Cancer Institute | Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use |
| US5519003A (en) * | 1994-02-01 | 1996-05-21 | Board Of Trustees Of The Leland Stanford Junior University | WD-40-derived peptides and uses thereof |
| JP3542181B2 (ja) * | 1994-10-21 | 2004-07-14 | 日本たばこ産業株式会社 | 新規タンパク |
-
1998
- 1998-12-09 FR FR9815545A patent/FR2774378A1/fr active Pending
-
1999
- 1999-01-29 AT AT99901671T patent/ATE356207T1/de not_active IP Right Cessation
- 1999-01-29 JP JP2000529429A patent/JP2002501746A/ja active Pending
- 1999-01-29 US US09/601,168 patent/US6730486B1/en not_active Expired - Fee Related
- 1999-01-29 DE DE69935414T patent/DE69935414T2/de not_active Expired - Lifetime
- 1999-01-29 WO PCT/FR1999/000196 patent/WO1999038969A1/fr active IP Right Grant
- 1999-01-29 CA CA002370098A patent/CA2370098C/en not_active Expired - Fee Related
- 1999-01-29 AU AU21694/99A patent/AU2169499A/en not_active Abandoned
- 1999-01-29 EP EP99901671A patent/EP1049775B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US6730486B1 (en) | 2004-05-04 |
| EP1049775A1 (de) | 2000-11-08 |
| FR2774378A1 (fr) | 1999-07-30 |
| CA2370098A1 (en) | 1999-08-05 |
| AU2169499A (en) | 1999-08-16 |
| CA2370098C (en) | 2008-04-29 |
| EP1049775B1 (de) | 2007-03-07 |
| WO1999038969A1 (fr) | 1999-08-05 |
| DE69935414T2 (de) | 2007-11-15 |
| DE69935414D1 (en) | 2007-04-19 |
| JP2002501746A (ja) | 2002-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200400241A1 (ru) | Направленные к мишени мультимерные контрастные вещества, основанные на пептидах | |
| EA200300381A1 (ru) | Нуклеиновые кислоты и полипептиды нового рецептора | |
| BR0213786A (pt) | Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células | |
| EA200400376A1 (ru) | Пептиды, полученные из казеина, и их использование в терапии | |
| EA199900355A1 (ru) | Теломераза обратная тринскриптаза | |
| DK161015C (da) | Blanding til anvendelse ved ekstern paavisning og lokalisering af en blodprop | |
| BR0211200A (pt) | Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células | |
| CY1111120T1 (el) | Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση | |
| DE60032486D1 (de) | Prion protein peptide und deren verwendung | |
| ATE356207T1 (de) | Humanes btrcp protein | |
| EA200000911A1 (ru) | Новые кристаллические формы антивирусного соединения бензимидазола | |
| EA199900621A1 (ru) | Лечение рассеянного склероза путем приема внутрь или ингаляции сополимера-1 | |
| ATE354638T1 (de) | Menschlicher gewebsinhibitor von metalloproteinase-4 | |
| CY1105380T1 (el) | Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων | |
| ATE306498T1 (de) | Von zellen präsentierte peptide | |
| ATE191922T1 (de) | Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen | |
| DE69931482D1 (de) | Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| BR9710975A (pt) | Genes de proteìna de adesão de superfìcie exposta de 120 kda imunodominante de ehrlichia chaffeensis | |
| EA200401390A1 (ru) | N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения | |
| DE50002164D1 (de) | Peptide zur inhibierung von hpv e6-proteinen | |
| ES2185652T3 (es) | Oligopeptidos derivados de fragmentos de proteinas c-reactiva. | |
| DE69738600D1 (de) | Neuroaktive peptide | |
| IT1283899B1 (it) | Peptidi e loro usi nella terapia della malattia celiaca | |
| ATE283279T1 (de) | Therapeutische inhaltsstoffe | |
| ATE528392T1 (de) | Neues protein und dessen dns |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |